• News

IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer -- Encouraging Five Year Clinical Data For Novel Next Generation Immuno-Oncology Therapy In Lung Cancer Presented at ESMO 2017 Congress --

Copenhagen, Denmark – October 12, 2017: IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today announced the appointment of Eva Ehrnrooth, M.D., Ph.D., to the position of chief medical officer.

Continue Reading